Keeping Track: Targeted Oncologics Tepmetko, Ukoniq Cleared; Posimir Earns Opioid-Sparing Language
Executive Summary
The latest US FDA approval news from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Outpatient Care, Self-Insured Employers Drive Growth Of Non-Opioid Pain Meds
Opioids are cheap, but the economics of clinical practice, including the shift of care from inside the hospital to outpatient or ambulatory facilities, are creating new opportunities for Pacira BioSciences’ non-opioid treatments for pain. Improved reimbursement and increased usage among anesthesiologists are the biggest revenue drivers for the company’s two marketed products.
Merck KGaA Moderates New Drug Sales Ambitions For 2022
Merck KGaA has narrowed its 2022 sales forecasts for its newly launched pharmaceuticals because of the COVID-19 pandemic, but still expects strong growth from these products and from products and services in its process solutions and electronic businesses.
Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.